Profusa Q3 2025 Earnings Report

Profusa EPS Results

• Actual EPS: -$52.50
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Profusa Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Profusa Announcement Details

• Quarter: Q3 2025
• Date: 11/19/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Profusa (NASDAQ:PFSA) develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making. Profusa’s business activities include research and development, clinical validation, regulatory engagement and partnerships with healthcare providers and life sciences organizations to integrate continuous tissue-level monitoring into diagnostic and therapeutic workflows.

Profusa operates primarily in the United States while engaging in broader clinical and collaborative activities internationally. The company is publicly listed on the Nasdaq exchange under the ticker PFSA. Additional details on leadership, specific regulatory approvals or product commercial status should be confirmed from the company’s public filings and investor communications for the most current information.